descriptionPublicationkeyboard_double_arrow_right Article 02 Jun 2011 English Publisher:Massachusetts Medical SocietyJournal:New England Journal of Medicine, volume 364, pages 2,166-2,169 (issn: 0028-4793, eissn: 1533-4406,

Authors: Bruno C. Medeiros; Megan Othus; Frederick R. Appelbaum;

doi: 10.1056/nejmc1104343 , 10.1056/nejmc1104343#sa3

pmid: 21631340 , 21631342 , 21631341

Cytarabine Dose for Acute Myeloid Leukemia

- Summary
- Subjects
- Metrics

No summary information available

Keywords

Antimetabolites, Antineoplastic, Remission Induction, Cytarabine, Middle Aged, Survival Analysis, Drug Administration Schedule, Leukemia, Myeloid, Acute, Monosomy, Treatment Outcome, fms-Like Tyrosine Kinase 3, Genes, Duplicate, Humans, Regression Analysis, Aged

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	340
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 1%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 1%